Avidity Biosciences plans to enter the clinic with its first in a new class of oligonucleotide-based treatments this year. The company will study its lead pipeline candidate, AOC 1001, in a Phase I/II trial in adults with myotonic dystrophy type 1 (DM1), set to start in the second half of the year. [Christoph Burgstedt / iStock / Getty Images Plus]
AOC 1001 is based on Avidity’s Antibody Oligonucleotide Conjugates (AOCs™) platform, designed to treat diseases of high unmet need by combining the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide therapies . . .
